Press Releases

CorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on Nephrology

Berkeley Heights, NJ – November 29, 2017 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that Chief Scientific Officer Antony Pfaffle, M.D., will host a practical workshop on hemodialysis catheter complications at the 17th Annual Conference on Nephrology, held December 4-5, 2017, in Dallas, TX.

Dr. Pfaffle joins 14 of the most influential speakers from around the world to lead discussions with nephrologists around current issues that are critical in the field.  His seminar will highlight, in part, the unmet need for preventing costly and life-threatening infections and thromboses in patients receiving hemodialysis through a central venous catheter, and data supporting the potential benefits of using Neutrolin® as a catheter lock solution.  Dr. Pfaffle will also serve as Chairperson for the second day of the conference, as well as an honorable guest at the pre-conference opening dinner.

Dr. Pfaffle commented, “I’m honored to participate in prestigious conference and host this important seminar with my colleagues in the nephrology community.  We all recognize the importance of preventing complications in hemodialysis patients who can’t afford to have their health further compromised.  Part of the discussion will focus on CorMedix’s anti-microbial and anti-thrombotic catheter lock solution, Neutrolin, which is currently in Phase 3 clinical development in the U.S. and already approved and marketed in the EU.  We look forward to a productive discussion around this and other ways that we can help enhance the quality of care and improve outcomes for patients with kidney disease who are on hemodialysis.”

About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels.  The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.  For more information, visit:

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to possible uses of taurolidine, that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the possible inability to capture sufficient CRBSI events in the ongoing Phase 3 clinical trial for Neutrolin® even with the reported changes to that trial; the cost, timing and results of the ongoing and planned Phase 3 trials for Neutrolin® in the U.S. and the resources needed to commence and complete those trials; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources and the impact on planned or future research, including for additional uses for taurolidine; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials; and the ability to retain and hire necessary personnel to staff our operations appropriately. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

For Investors & Media:
Dan Ferry
LifeSci Advisors, LLC